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ABSTRACT
Background. This article presents prospective lower bound estimations of findings on prevalence,
incidence, clinical correlates, severity markers, co-morbidity and course stability of threshold and
subthreshold recurrent brief depressive disorder (RBD) and other mood disorders in a community
sample of 3021 adolescents.
Method. Data were collected at baseline (age 14–17) and at two follow-up interviews within an
observation period of 42 months. Diagnostic assessment was based on the Munich Composite
International Diagnostic Interview (M-CIDI).
Results. Our data suggest that RBD is a prevalent (2.6%) clinical condition among depressive
disorders (21.3%) being at least as prevalent as dysthymia (2.3%) in young adults over lifetime.
Furthermore, RBD is associated with significant clinical impairment sharing many features with
major depressive disorder (MDD). Suicide attempts were reported in 7.8% of RBD patients, which
was similar to MDD (11.9%). However, other features, like gender distribution or co-morbidity
patterns, differ essentially fromMDD.Furthermore, the lifetime co-occurrence ofMDDandRBDor
combined depression represents a severe psychiatric condition.
Conclusions. This study provides further independent support for RBD as a clinically significant
syndrome that could not be significantly explained as a prodrome or residual of major affective
disorders.
INTRODUCTION
Concept and previous findings
Since the introduction of explicit symptom and
duration criteria for mood disorders in ICD-10
and DSM-IV, the appropriateness of these
threshold definitions for specific disorders has
been investigated in several studies (Wittchen
et al. 1998a, b, 2000; Angst et al. 2000a, b). At
the core of these findings stands the repeated
demonstration that even patients who fall
short of stringent diagnostic criteria (e.g. major
depressive disorder (MDD)) reveal substantial
suffering, impairment and correlates of clinical
significance such as increased incidence of suicide
attempts. Thus, boundaries of disorders within
the mood disorder spectrum, as well as their
delineation from other disorders, are not yet
resolved (Kendler & Gardner, 1998).
Among the many attempts to identify such
clinically significant expressions of mood dis-
orders recurrent brief depressive disorder (RBD)
has evolved as a particularly promising concept
(Angst et al. 2000b ; Kasper et al. 2000; Pezawas
et al. 2001). RBD has been defined by presenting
the same full-blown picture of depression as
MDD, but failing tomeet themandatory 2weeks
duration criterion. Additionally, brief depressive
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episodes have to occur about monthly, being
independent of the menstruation cycle within an
observation period, lasting 12 months.
The clinical significance and supportive vali-
dation work on RBD has been reported in psy-
chiatry for more than a century (Angst, 1994a).
An operationalized definition of RBD has been
introduced in 1985 referring to the results of the
Zurich-Study (Angst & Dobler-Mikola, 1985).
During this observation period a 9.8% lifetime
prevalence of RBD (Angst, 2000a) similar to
MDD has been found. In this study the syn-
dromal and associated features of RBD, suf-
ficiently unique patterns of course and its clinical
significance in terms of impairment and various
clinical correlates have been worked out (Angst,
1994b). The particularly high suicide attempt
risk of subjects with RBD was noted. These
findings have been supported by a comprehen-
sive World Health Organization (WHO) project
on ‘Psychological problems in general health
care ’ and further associated studies (Sartorius
et al. 1993) in primary care settings.Notably, two
centres confirmed patterns of clinical significance
in this study (Maier et al. 1994a, b ; Weiller et al.
1994a). Furthermore, prevalence rates of RBD
are available for 15 different international pri-
mary care settings ranging from 3.7% to 5.7%
(Weiller et al. 1994b). Also, results of an inde-
pendent general population survey in Sardinia
revealed aswell a high lifetime prevalence (6.9%)
of RBD associated with an increased suicide
risk and alcohol abuse (Altamura et al. 1995).
However, a contradictory low clinical prevalence
rate (2%) was reported in the DSM-IV Mood
Disorder Field Trial (Keller et al. 1995).
Subsequently, other studies including a com-
munity enquiry (Snaith, 2000) have provided
substantial further evidence of RBD in terms of
clinical validation in studies on seasonal patterns
of RBD (Kasper et al. 1994), and the provision of
biological support (Montgomery et al. 1989;
Staner et al. 1992; De la Fuente et al. 2002; Pe-
zawas et al. 2002a). Retrospectively evaluated
patterns of duration in epidemiological studies
have been supported by prospective clinical
studies (Post et al. 1998; Pezawas et al. 2002b).
Additionally, several controlled treatment stud-
ies (Montgomery et al. 1994; Kocmur et al.
1998; Pazzaglia et al. 1998; Verkes et al. 1998;
Wermuth et al. 1998), one open trial (Sta-
menkovic et al. 2001), one single case analysis
(Pezawas et al. 2002b) and case reports (Gertz,
1992; Joffe, 1996; Amore et al. 1998; Corominas
et al. 1998; Stamenkovic et al. 1998) investigated
drug response in RBD and documented the need
for treatment. The clinical significance of this
diagnostic concept has further been underlined
by studies on patterns and consequences of a
lifetime co-occurrence of both, RBD and MD,
called combined depression (CD) (Montgomery
et al. 1989), which has been further developed
byAngst (1990). Epidemiological (Angst, 1994b ;
Maier et al. 1994a) and clinical (Montgomery
et al. 1989; Pezawas et al. 2002a) studies de-
monstrated a dramatic increase of suicide at-
tempt rates and measures of impairment in the
case of CD in comparison to either single RBD
or MD.
Based on such epidemiological findings RBD
has been integrated as a distinct mood disorder
diagnosis into ICD-10 and as research diagnosis
in the appendix of DSM-IV with the need of
systematic future research to support the in-
dependent status of RBD. Nevertheless, some
significant reservations regarding RBD as an in-
dependent and new diagnostic category remain,
mainly due to the following concerns : (1) Is there
sufficient evidence that RBD is more than either
a prodromal, residual or an associated severity
marker of mood or even other existing psycho-
pathological conditions? ; (2) Is RBD sufficiently
frequent and disabling in psychosocial and clini-
cal terms in the community and clinical settings
to deserve further research emphasis? ; (3) To
what degree are data available demonstrating
consistently and sufficiently unique patterns of
vulnerability and risk factors for first onset and
pathogenesis of RBD?
Aims
In order to provide further research data per-
taining to these critical issues focusing especially
on adolescents and young adults, this paper
presents findings on the prevalence, incidence,
correlates and patterns of co-morbidity of RBD
defined by stringent research diagnostic criteria
from a large-scale epidemiological study with a
total of more than 3000 respondents, who were
followed over a period of almost 4 years in a total
of three waves (Lieb et al. 2000). Unlike most
other studies on RBD, it is noteworthy that
the study was not specifically designed for the
evaluation of RBD. However, as part of the
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standardized diagnostic assessment the study
included a separate diagnostic module for RBD,
that was administered in only those respondents
with no signs of a major depressive episode
within the past 12 months. In the light of pre-
vious findings this constitutes a particular re-
strictive test to explore the frequency of RBD
resulting in lower bound estimates in terms of
prevalence and incidence, and also provides new
data about RBD in a particularly young sample
aged 14–24 at the outset of this study.
Specific aims of this paper are : (1) estimation
of the (lower bound) prevalence for RBD along
with a description of its symptoms, frequency
and duration patterns in a community sample of
adolescents and young adults ; (2) a comparison
of RBD,MDDandCD associated impairments/
disability as well as other clinical correlates in
this sample and to determine excess markers;
and, (3) a description of 12-month and lifetime
patterns of co-morbidity in RBD or CD.
METHOD
Design
The overall design of the Early Developmental
Stages of Psychopathology Study (EDSP) is a
prospective longitudinal design based on a
representative community sample of 3021 ado-
lescents and young adults living in the Munich
area. The age range for the targeted population
was chosen to address especially the early de-
velopmental stages of substance use, abuse and
dependence and other mental disorders. The
EDSP study consists of a baseline investigation,
two follow-up investigations and an independent
parent survey. Because of the focus on early
developmental stages of psychopathology and
substance use, only the younger cohort of ado-
lescents, aged 14–17 at baseline, was examined
in the first follow-up investigation. In the final
follow-up investigation, the entire baseline
sample was assessed again. Methodological as-
pects of this study have been described in greater
detail elsewhere (Lieb et al. 2000).
Sample
TheEDSP sample was drawn randomly from the
1994 government population registers of resi-
dents in metropolitan Munich and the sur-
rounding counties with an expected age range for
the sampled subjects between 14 and 24 at the
time of the baseline interview in 1995. As the
study was designed as a longitudinal panel with
special interest in early developmental stages of
psychopathology, 14–15-year-olds were sampled
at twice the probability of people 16–21 years of
age, and 22–24-year-olds were sampled at half
the probability of the 16–21-year-olds. From the
total of 4809 sampled individuals, 4263 were
located and determined to be eligible for the
study. Sampled individuals whowere not located
were disproportionately older. In comparison
to located subjects, subjects who could not be
contacted had either moved outside the metro-
politanMunich area in the time interval between
their registration and the beginning of the study
in 1995 (8.8%) or they could not be found with
the listed address during the fieldwork period
(2.4%). From the 4263 individuals a total of
3021 could be assessed at baseline (T0, response
rate=71%). Informed consent was obtained
from the participants.
The first follow-up study (T1) was conducted
only for subjects aged 14–17 at baseline, whereas
the second follow-up study (T2) was conducted
for all subjects. In the first follow-up, an average
of 20 months after baseline, a total of 1228 in-
terviews were completed (response rate=88%).
From the 3021 subjects of the baseline-study,
a total of 2548 interviews were completed at
the second follow-up, which was conducted an
average of 42 months after baseline (response
rate=84%). There was no selective attrition
due to age, gender, or geographic distribution
between the baseline and second follow-up
investigation. More details about the sampling
and representativeness of the whole EDSP-
sample along with its sociodemographic charac-
teristics and a detailed list of reasons for non-
response have been reported elsewhere (Lieb
et al. 2000).
Diagnostic assessment
In all three waves, symptom and diagnostic as-
sessment were based on the computer-assisted
version of the Munich-Composite International
Diagnostic Interview (M-CIDI) (Wittchen &
Pfister, 1997). The M-CIDI is an updated ver-
sion of the World Health Organization’s CIDI
version 1.2 (World Health Organization, 1990)
incorporating questions that assess DSM-IV
and ICD-10 criteria. The M-CIDI allows for
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the standardized assessment of symptoms, syn-
dromes and diagnoses of a wide range of DSM-
IV substance use and mental disorders along
with information about onset, duration, clinical
and psychosocial severity. Links to publications
on M-CIDI and further aspects of general di-
agnostic assessment in this study can be seen
elsewhere (Lachner et al. 1998; Wittchen et al.
1998a, b).
At baseline, the lifetime version of theM-CIDI
was used. At each of the follow-up assessments,
the M-CIDI interval version, which refers to the
time period of assessment from the last interview
until the present, was applied. For those re-
spondents aged 14–17 at baseline, the complete
follow-up status T0–T2 is assessed from the ag-
gregation of information obtained from the T1
and T2 interviews. For respondents aged>17 at
baseline, the complete follow-up status is as-
sessed from the second follow-up questions,
which cover the time between T0 and T2.
Assessment of MDD and dysthymia
Besides thresholdMDD it is possible to compute
from the M-CIDI subthreshold MDD (sMDD)
using the WHO-CIDI algorithm (Üstün & Sar-
torius, 1996). This diagnosis is assigned when
respondents fall short of just one diagnostic
criterion, by failing to report either the manda-
tory five of a total of nine DSM-IV symptoms
(criterion A) or clinical significant distress or
impairment (criterion C). According to DSM-IV
rules, the diagnosis of dysthymia can only be
made if dysthymic symptoms appeared at least
2 years prior to the first MDD episode, or if
there has been a full remission of at least 2
months of MDD episode before the onset of
dysthymia.
Assessment of RBD
RBD has been assessed by M-CIDI. Since the
assessment of RBD in this study is crucial for the
comparison to other studies, we will describe
RBD evaluation in detail. The stem question was
the same as forMDD episodes (depressive mood
or loss of interest) except duration, which in
RBD had to persist for<2 weeks. Additionally,
number of brief depressive episodes during the
last 12 months (or since the last interview), their
average and maximal duration was evaluated.
Furthermore, the presence and absence of all
35 psychopathological symptoms of depression
covered by the MDD section of the CIDI were
assessed. The threshold diagnosis of RBD used
in this paper followed ICD-10 research diag-
nostic criteria (about monthly appearance, in-
dependence of the menstruation cycle,<2 weeks
duration). Subthreshold RBDwas defined either
reporting<8 episodes per year or falling beyond
the mandatory psychopathological criteria of
depression as already reported for sMDD. CD
was longitudinally defined in this study as life-
time co-occurrence of RBD and MDD includ-
ing subthreshold manifestations using the same
procedures being mentioned above (e.g. MDD
at baseline and RBD at T1 was labelled as
CD, etc.).
However, two issues have to be pointed out,
which in this investigation can be seen as being
a restrictive test for the concept of RBD. First,
RBD has not been evaluated at T0, which may
lead to an underestimation of the true cumulative
incidence rate of RBD. Secondly, the branching
structure of M-CIDI (and most other common
interviews) determines that a subject is only
asked for brief depressive episodes in case of a
denial of MDD stem questions. This hierarchy
determines that RBD cases have only been
identified within this study in the absence of
MDD either at T1 or T2. Therefore, results on
RBD evaluated in this study can be seen as lower
bound estimates.
Statistics
To account for different sampling probabilities
for the different age groups, non-contact and
non-response, all measures were estimated using
weighted data. For the analyses of associations
between bivariate variables, logistic regressions
for binary responses (odds ratio OR) were used.
For quantitative outcomes (e.g. number of im-
paired days) negative binomial regressions were
used. Associations are described by so-called
incidence rate ratios (IRRs), i.e. the factor by
which the mean differs from that of the com-
parison group. Analyses were performed using
the Stata software package (StataCorp, 2001)
and applying the Huber-White sandwich matrix
for weighted data (Royall, 1986), including them
as independent variables in the respective model
controlled for sex and age of the respondents. All
lifetime prevalences provided in this paper rep-
resent lifetime-to-date prevalences (P<0.05 was
considered as statistically significant).
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RESULTS
Cumulative incidence of RBD and other
depressive disorders
Already at baseline, depressive disorders have
been highly prevalent in our sample (21.3%).
The upper portion of Table 1 shows the lifetime
prevalence of depressive disorders assessed at
baseline and the (cumulative) incidence over the
4-year follow-up period. At baseline, 12.5% of
the sample aged 14–24 reported at least one
episode of MDD according to DSM-IV criteria
over their lifetime; and additional 6.5% fulfilled
criteria for subthreshold depression and 2.4%
for dysthymia. No estimates for RBD were
available for the baseline investigation.
In the follow-up period, in additional 344 and
136 cases, unaffected at baseline reported inci-
dent episodes of either threshold (13.9%) or sub-
threshold (5.1%) MDD, and another 63 cases
fulfilled criteria for dysthymia (2.3%). At either
the first or second follow-up a total of 71 subjects
(2.6%)met criteria for threshold or subthreshold
RBD among which the majority were threshold
RBD cases (1.9%). These estimates do not take
into account other diagnostic hierarchies or
exclusions (schizophrenia and other psychotic
disorders) for neither RBDnorMDD.However,
bipolar II and I disorder were excluded.
Taking into account co-occurrences between
RBD/sRBD and MDD/sMDD (lower portion
of Table 1), 1.2% (0.5%) reported RBD (sRBD)
without lifetime history of MDD or sMDD and
1% reportedRBDor sRBDwith lifetime history
of MDD or sMDD. This indicates that among
all depressive disorders the proportion of RBD/
sRBD is at least 12%.
In the remainder of the paper all comparisons
will be based on the RBD cases as defined in the
lower portion of Table 1, thus specifying whether
RBD or sRBD occurred without or within
(combined depression) the lifetime history of
MDD/sMDD.
Gender
Controlling for age, MDD and dysthymia, but
not RBD revealed significant differences with
regard to sex (Table 2). Whereas there is a sig-
nificant 2 : 1 preponderance of females in the
former, there is a slight, yet not significant pre-
ponderance of males in RBD except CD.
Profile of depressive symptoms in RBD, MDD
and their subthreshold manifestations
Table 3 compares the frequency of depressive
symptoms in five mutually exclusive groups of
depression. Highest overall symptom counts
were found for CD (mean 7.3, 95%CI 6.6–7.9)
followed by the MDD group (mean 6.2, 95%CI
6.0–6.4). The sRBD group (mean 2.1, 95%CI
1.9–2.3) revealed the lowest mean number of
Table 1. Prevalence rates of assessed depressive disorders among study participants of three waves
Frequencies of depressives disorders at
baseline and before (N=3012)
Cumulative frequencies of depressive
disorders after baseline until the last wave
N %w (95%CI) N %w (95%CI)
Any depressive disorder# 467 20.3 (18.6–22.2) 549 21.3 (19.6–23.2)
– any MDD 272 12.5 (11.1–14.1) 344 13.9 (12.5–15.5)
– any sMDD 164 6.5 (5.5–7.7) 136 5.1 (4.2–6.1)
– Dysthymia 60 2.4 (1.8–3.2) 63 2.3 (1.8–3.0)
– any RBD/sRBD NA NA 71 2.6 2.0–3.4)
– any RBD NA NA 52 1.9 (1.4–2.6)
– any sRBD NA NA 19 0.7 (0.4–1.2)
RBD subgroups based on course
information any RBD/sRBD,
never MDD/sMDD
NA NA 48 1.6 (1.2–2.2)
– any RBD, never MDD/sMDD NA NA 34 1.2 (0.8–1.7)
– any sRBD, never MDD/sMDD NA NA 14 0.5 (0.3–0.8)
any RBD/sRBD and NA NA 23 1.0 (0.6–1.6)
MDD/sMDD$
MDD, Major depressive disorder; RBD, recurrent brief depressive disorder ; sMDD, subthreshold MDD; sRBD, subthreshold RBD;
NA, not evaluated at baseline; N, unweighted N ; %w, weighted to reflect the sampling scheme; CI, confidence interval.
# Without using diagnostic hierarchies and exclusions.
$ Combined depression.
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symptoms as compared to RBD (mean 4.0,
95%CI 3.7–4.4) and sMDD cases (mean 4.5,
95%CI 4.4–4.8). Comparing the confidence in-
tervals of the means, RBD cases did not differ
from sMDD cases regarding to the overall
symptom count.
A comparison between RBD and MDD cases
revealed thatMDD cases reported a significantly
higher frequency of depressed mood (OR 3.1,
95%CI 4.2–25.1), loss of interest or pleasure
(OR 3.1, 95%CI 1.4–6.7), change in appetite
(OR 3.2, 95%CI 1.4–7.3), change in psycho-
motor activity (OR 3.7, 95%CI 1.3–10.7), loss of
confidence/self-esteem, feelings of self-reproach/
guilt (OR 2.5, 95%CI 1.1–5.4), diminished
ability to think/concentrate (OR 9.6, 95%CI
4.0–23.4) and recurrent thoughts of death/
suicide, or suicidal behaviour (OR 9.6, 95%CI
3.5–26.2). No significant differences have been
found concerning decreased energy or increased
fatigability and sleep disturbance of any type.
Interestingly, only sleep disturbances had a
tendency towards a higher frequency in RBD.
Nevertheless, a comparison between CD and
MDD cases showed that CD cases reported
significantly more frequently loss of interest or
pleasure (OR 5.1, 95%CI 1.4–18.0), decreased
energy or increased fatigability (OR 3.4, 95%CI
1.2–12.8), loss of confidence/self-esteem, feelings
of self-reproach/guilt (OR 5.6, 95%CI 1.2–25.0).
In contrast, CD cases reported significantly less
frequently a diminished ability to think/con-
centrate (OR 0.2, 95%CI 0.1–0.7) than MDD
cases. However, no significant difference has
been found in CD cases as compared to RBD
cases concerning this symptom.
Focusing on the comparison of the three
groups exhibiting recurrent brief depressive
episodes (RBD, sRBD, CD), a similar high
number of episodes (13.4–15.9) with a similar
average number of days being affected during
any 12-month period (38.5 to 48.5) has been re-
ported. CD cases revealed the highest values in
both comparisons. There is a clear preponder-
ance of typical brief depressive episodes with an
average duration of 4.3 days in the CD, 4.1 days
in the RBD and 4.6 in the sRBD group.
A comparison of clinical correlates of brief and
major depressive episodes
Compared to cases with no MDD/RBD all
groups, except for sRBD, revealed a significantly
increased level of current subjective complaints
present at T1 or T2.
In comparison to cases without MDD and
RBD all investigated depression groups of RBD
(OR 3.2, 95%CI 1.2–8.6), sMDD (OR 2.7,
95%CI 1.5–4.8), MDD (OR 4.7, 95%CI 3.3–
6.7) and CD (OR 4.2, 95%CI 1.5–12.3) reported
significant higher rates of impairment or dis-
ability at T2 with the exception of sRBD. How-
ever, MDD cases did not significantly differ
from RBD and CD cases with respect to im-
pairment or disability at T2. Similarly, disabled
or impaired days within the last month at T2
among impaired between investigated de-
pression groups of sMDD (IRR 2.2, 95%CI 1.4–
3.4), MDD (IRR 3.7, 95%CI 2.2–6.2) and CD
(IRR 4.5, 95%CI 1.5–13.0) showed a signifi-
cantly increased number of impaired/disabled
days with the exception of sRBD (IRR 0.9,
95%CI 0.2–4.5) and RBD (IRR 1.1, 95%CI
0.3–4.0) as compared to subjects without MDD
and RBD. Furthermore, MDD subjects did not
differ significantly fromCDorRBDwith respect
to the number of impaired/disabled days.
With regard to mental health treatment all
groups – except for sRBD – also had a similar
proportion of cases reporting a mental health
treatmentover theobservationperiod.RBD(OR
4.3, 95%CI 2.0–9.4), sMDD (OR 4.6, 95%CI
2.7–8.0), MDD (OR 3.9, 95%CI 2.9–5.3) and
CD (OR 4.7, 95%CI 1.8–12.5) reported higher
rates of treatment seeking in comparison to
subjects without MDD and RBD.






2.0 1.3 0.6 (0.3–1.2)
Any RBD, never MDD/sMDD 1.4 1.0 0.7 (0.3–1.5)
Any sRBD, never MDD/sMDD 0.6 0.3 0.5 (0.2–1.6)
Any RBD/sRBD and
MDD/sMDD#
0.8 1.1 1.3 (0.5–3.4)
Any MDD, never RBD/sRBD 9.2 16.9 2.0* (1.5–2.6)
Any sMDD, never RBD/sRBD 3.7 6.1 1.7* (1.1–2.6)
Dysthymia 1.7 3.0 1.8* (1.0–3.2)
%w, Weighted to reflect the sampling scheme, OR, odds ratio
controlled for age; CI, confidence interval ; MDD, major depressive
disorder ; RBD, recurrent brief depressive disorder ; sMDD, sub-
threshold MDD; sRBD, subthreshold RBD.
# Combined depression.
* P<0.05.
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All investigated groups of RBD (OR 3.6,
95%CI 1.6–8.1), sMDD (OR 3.5, 95%CI 2.0–
6.2), MDD (OR 5.9, 95%CI 4.3–8.0) and CD
(OR 3.7, 95%CI 1.4–9.8) except sRBD were
significantly more likely than subjects without
RBD and MDD to report suicidal ideation.
Suicide attempts have been reported in all groups
except sRBD andCD (Table 4). Suicide attempts
occurred significantlymore often in subjects with
MDD (OR 6.4, 95%CI 3.5–10.2), sMDD (OR
26.6, 95%CI 4.8–147.6) and RBD (OR 4.1,
95%CI 1.1–15.9) than in subjects withoutMDD
and RBD. About 10% of RBD and MDD sub-
jects reported suicide attempts until T2 (Table 4).
However, missing reports of suicidal attempts in
the CD group might be attributable to the small
sample size and the CD definition used in this
paper including subthreshold cases.
A comparison of the Symptom Check List-90
(SCL-90) values evaluating psychiatric symp-
toms in the last week between subjects not af-
fected with MDD and RBD and investigated
depression groups revealed increased values in
subjects with RBD (IRR 0.7, 95%CI 0.3–1.1),
sMDD (IRR 0.5, 95%CI 0.3–0.7), MDD (IRR
0.8, 95%CI 0.7–1.0), and CD (IRR 0.6, 95%CI
0.1–1.1) with the exception of sRBD (IRR 0.2,
95%CI 0.3–0.6). However, MDD subjects did
not differ significantly from RBD and CD.
Patterns of co-morbidity
In terms of co-morbid conditions, Table 5 reveals
that the majority of cases in the investigated
depression groups have mostly several lifetime
co-morbid conditions in comparison to subjects
without MDD and RBD.
Table 3. Depression symptom profiles of studied groups
Symptoms
sRBD (N=14) RBD (N=34) sMDD (N=136) MDD (N=344) CD (N=23)
N %w N %w N %w N %w N %w
Depressed mood 3 18.7 18 55.9 107 81.2 302 92.4 22 98.0
Loss of interest or pleasure 4 32.6 16 39.8 46 37.4 216 66.1 20 90.9
Change in appetite 2 11.1 10 33.4 57 39.6 207 64.0 17 80.8
Sleep disturbance of any type 9 68.7 29 90.4 91 68.0 274 85.0 23 100.0
Change in psychomotor activity 0 0.0 5 10.6 31 21.5 90 27.6 7 35.6
Decreased energy or increased fatigability 3 26.0 17 54.0 65 50.1 213 66.0 19 88.2
Loss of confidence/self-esteem, feelings of
self-reproach/guilt
3 17.5 16 45.1 65 51.9 218 67.4 21 91.9
Diminished ability to think/concentrate 5 29.9 20 55.8 106 79.7 295 90.5 16 71.1
Recurrent thoughts of death/suicide,
or suicidal behaviour
1 3.5 6 16.7 48 31.7 207 59.8 16 69.4
Mean (S.E.) Mean (S.E.) Mean (S.E.) Mean (S.E.) Mean (S.E.)
Overall depression symptom count 2.1 (0.1) 4.0 (0.2) 4.6 (0.1) 6.2 (0.1) 7.3 (0.3)
MDD, Major depressive disorder; RBD, recurrent brief depressive disorder ; sMDD, subthreshold MDD; sRBD, subthreshold RBD;
CD, combined depression; N, unweighted N ; %w, weighted to reflect the sampling scheme; S.E., standard error.
Table 4. Clinical correlates of studied depression groups
sRBD RBD sMDD MDD CD
N %w N %w N %w N %w N %w
Impaired/disabled at T2 2 7.4 6 18.0 20 14.4 74 22.5 6 21.2
Treatment 0 0.0 12 38.7 35 29 124 38.7 10 42.5
Suicidal ideation 1 4.0 10 28.9 29 17 131 37.2 7 27.8
Suicide attempts 0 0.0 3 7.8 6 4 41 11.9 0 0.0
Mean (S.E.) Mean (S.E.) Mean (S.E.) Mean (S.E.) Mean (S.E.)
SCL-90 total score 0.3 0.1 0.4 0.1 0.3 0.1 0.4 0.0 0.4 0.1
Impaired/disabled days (T2)# 1.2 0.2 2.0 0.9 2.8 0.3 4.6 1.0 5.1 2.0
MDD, Major depressive disorder ; RBD, recurrent brief depressive disorder ; sMDD, subthreshold MDD; sRBD, subthreshold RBD;
CD, combined depression; N, unweighted N ; %w, weighted to reflect the sampling scheme; S.E., standard error.
# Among impaired during the last month.
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In contrast to MDD, which was associated
with most major mental disorders displayed in
Table 5, RBD showed a more distinct profile of
co-morbid disorders. Significant 12-month co-
morbidities were found for any anxiety disorder
(OR 3.9, 95%CI 1.7–9.2), especially agora-
phobia (OR 10.1, 95%CI 1.2–86.0) and specific
phobias (OR 3.3, 95%CI 1.2–8.8). However,
post-traumatic stress disorder exhibited the
highest 12-month co-morbidity (OR 12.9,
95%CI 1.4–115.5). It is noteworthy that none
of the RBD cases fulfilled criteria for DSM-IV
12-month or lifetime premenstrual dysphoric
disorder. In contrast to MDD no 12-month as-
sociations were found for panic disorder, social
phobia, generalized anxiety disorder, obsessive–
compulsive disorder, any somatoform disorder,
eating disorders, any hypomania, any bipolar
disorder and as well as any substance use dis-
order. Lifetime co-morbidities were significantly
increased in RBD for any anxiety disorder,
agoraphobia, social phobia and alcohol abuse
(Table 5). In contrast,MDDwas associated with
an increase in all major mental disorders. In the
case of CD more 12-month and lifetime co-
morbidities than in RBD were found as com-
pared to subjects without MDD and RBD. In
contrast to RBD, CD was associated with severe
conditions like illegal drug dependence as com-
pared to subjects without MDD and RBD dur-
ing 12-months and lifetime.
Overall 14.7% of RBD cases occur with no
lifetime co-morbid condition, similar to the
proportion of lifetime MDD (11.3%) (Table 6).
RBD exhibited a significant lower multi-
morbidity in terms of lifetime (more than four
associated disorders) co-morbidity than MDD
(OR 3.9, 95%CI 1.1–14.4). Nevertheless, 12-
month (one associated disorder) co-morbidity
was significantly higher for RBD than MDD
(OR 0.4, 95%CI 0.2–0.9).
Only 6.9% of CD cases had no additional
lifetime diagnosis indicating a pattern of multi-
morbidity. CD cases even showed a significantly
higher 12-month co-morbidity for one additional
associated disorder (OR 2.7, 95%CI 1.1–7.0)
Table 5. Lifetime associated major mental disorders in RBD, MDD, CD in comparison to controls
without RBD/MDD
RBD MDD CD
%w OR (95%CI) %w OR (95%CI) %w OR (95%CI)
Any anxiety disorder 46.5 2.5* (1.1–5.5) 61.3 3.8* (2.9–5.0) 63.8 4.5* (1.8–11.3)
Agoraphobia w/o panic disorder 4.4 2.9 (0.4–18.4) 9.8 5.5* (3.0–10.1) 20.6 14.4* (4.7–44.2)
Panic disorder# 0.0 — — 8.9 7.2* (3.6–14.4) 14.5 13.5* (4.0–45.0)
Social phobia 15.8 3.2* (1.1–8.9) 23.8 4.7* (3.2–6.8) 11.7 2.0 (0.6–7.2)
Specific phobia 23.0 1.5 (0.6–3.7) 38.0 2.7* (2.0–3.6) 45.0 3.8* (1.4–10.2)
Phobia NOS 11.9 2.1 (0.6–6.6) 10.5 1.5 (1.0–2.4) 14.0 2.3 (0.6–8.4)
GAD 0.0 — — 11.8 9.7 (5.0–19.0) 9.4 8.3* (1.7–39.2)
OCD 0.0 — — 4.1 5.0* (2.1–11.9) 3.2 3.9 (0.5–31.9)
PTSD 3.7 6.7 (0.8–57.1) 7.4 11.0* (4.8–25.3) 3.6 5.6 (0.7–45.2)
Any somatoform disorder 36.9 1.5 (0.7–3.5) 56.4 2.8* (2.2–3.7) 37.2 1.3 (0.6–2.9)
Any affective disorder 19.0 3.7* (1.5–9.1) 100.0 — — 81.7 69.9* (21.7–224.8)
Hypomania/mania 3.7 1.3 (0.3–5.7) 3.0 0.9 (0.4–1.9) 0.0 — —
Any bipolar disorder 0.0 — — 11.8 17.7* (9.1–34.3) 0.0 — —
PMDD 0.0 — — 16.2 4.1* (2.3–7.3) 15.9 4.1 (0.8–19.8)
Any eating disorder 5.8 2.7 (0.4–19.2) 11.8 4.0* (2.3–6.8) 10.9 4.2* (1.1–16.3)
Any anorexia 0.0 — — 5.7 2.8* (1.4–5.5) 4.1 2.2 (0.3–17.3)
Any bulimia 5.8 6.2 (0.9–43.4) 8.0 5.6* (2.7–11.5) 10.9 9.6* (2.2–42.4)
Any substance-related disorder 52.2 1.7 (0.8–3.7) 54.1 2.2* (1.7–2.9) 57.2 2.3 (1.0–5.7)
Nicotine dependence 28.5 1.6 (0.7–3.5) 39.4 2.7* (2.0–3.5) 39.0 2.6 (1.0–6.6)
Alcohol abuse 39.3 2.4* (1.0–5.8) 24.7 1.6* (1.2–2.2) 37.5 2.8* (1.1–6.9)
Alcohol dependence 3.7 0.4 (0.1–1.9) 13.8 2.7* (1.7–4.1) 11.5 1.8 (0.4–7.9)
Illegal drug abuse 1.9 0.3 (0.0–1.9) 10.2 2.5* (1.6–4.0) 12.2 2.8 (0.9–9.4)
Illegal drug dependence 8.1 4.2 (1.0–18.3) 5.9 3.5* (1.8–6.7) 21.2 14.4* (3.8–54.6)
MDD, Major depressive disorder; RBD, recurrent brief depressive disorder ; CD, combined depression; %w, weighted to reflect the
sampling scheme interval ; OR, odds ratio; CI, confidence interval ; NOS, not otherwise specified; GAD, generalized anxiety disorder; OCD,
obsessive–compulsive disorder; PTSD, post-traumatic stress disorder ; PMDD, premenstrual dysphoric disorder.
# With or without agoraphobia.
* P<0.05.
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and a higher lifetime co-morbidity for three ad-
ditional associated disorders than MDD (OR
3.1, 95%CI 1.0–9.2).
The relatively few cases in the first wave of
RBD assessment do not allow for a statistical
analysis of course characteristics. However, our
data do not support the hypothesis that RBD is a
prodromal or a residual state ofMDD since only
4% of subjects with any depressive disorder had
a dual diagnosis. The majority of RBD subjects
developed RBD in T2 without a prodromal di-
agnosis of MDD, sMDD, or even sRBD at T1.
Only five MDD cases developed RBD either at
T1 and T2. It seems noteworthy that 13 out of 20
RBD cases have been diagnosed without any
other assessed threshold or subthreshold affect-
ive disorder within all three waves.
DISCUSSION
Themain aim of this paper was to re-examine the
concept of RBD in a community sample of
adolescents and young adults under a restrictive
condition, free of any bias towards an over-
estimation of this diagnosis, which seemed to be
necessary due to restraints in the scientific com-
munity concerning the concept of RBD (Keller
et al. 1995). Since this is the largest community
sample ever studied in the context of RBD, we
consider our findings to be a major contribution
to the awareness of the scientific community
towards the concept of RBD.
Recurrent brief depressive disorder
Largely consistent with other epidemiological
studies our data confirm the concept of RBDas a
relatively prevalent and clinical relevant affective
disorder exhibiting several features being distinct
from MDD. Threshold and subthreshold RBD
have been found to account for at least 12% of
all depressive syndromes in the community being
at least as prevalent as dysthymia. However,
prevalence rates for RBD are substantially lower
in this study than reported in other community
studies reporting prevalence rates up to 50% of
all depressive cases in the community or gen-
eral health care (Maier et al. 1994a ; Weiller et al.
1994a, b ; Altamura et al. 1995; Angst et al.
2000a, Snaith, 2000). Taking the hierarchy of
CIDI-M into consideration, this is similar to
other diagnostic interviews, which diagnose
RBD only in the absence of MDD or its sub-
threshold manifestation, these prevalence rates
can be taken as lower bound estimations. In
order to estimate lost RBD cases in our study
by the hierarchy of M-CIDI, we calculated
both, hierarchical and non-hierarchical pre-
valence rates of the sample investigated in the
Zurich Study. These results suggest that we only
lost 10% (maximum 20%) of RBD cases by the
diagnostic hierarchy used in our study (Angst,
2001; personal communication).
In accordance with other epidemiological
studies (Maieretal. 1994a ;Weiller etal. 1994a,b ;
Altamura et al. 1995; Angst, 2000a ; Snaith,
Table 6. Acute and chronic multi-morbidity in RBD, MDD, CD in comparison to controls without
RBD/MDD
RBD MDD CD
%w OR (95%CI) %w OR (95%CI) %w OR (95%CI)
Lifetime
0 14.7 0.3 (0.1–0.8) 11.3 0.2* (0.1–0.3) 6.9 0.1* (0.0–0.9)
1 35.9 1.1 (0.5–2.4) 20.7 0.5* (0.4 –0.7) 17.5 0.4 (0.1–1.2)
2 33.5 2.4* (1.1–5.3) 29.2 1.9* (1.4 –2.6) 26.7 1.7 (0.7–4.5)
3 8.5 1.2 (0.3–4.7) 13.7 2.1* (1.4 –3.1) 33.1 6.3* (2.2–18.3)
o4 7.5 2.3 (0.6–8.5) 25.1 9.0* (6.1–13.5) 15.8 5.1* (1.8–15.0)
12-months
0 38.6 0.3* (0.2–0.7) 38.4 0.3* (0.2–0.4) 27.5 0.2* (0.1–0.6)
1 49.0 2.6* (1.2–5.5) 28.9 1.1 (0.8–1.5) 52.2 3.0* (1.2–7.4)
2 12.3 2.3 (0.8–6.8) 18.8 3.6* (2.5–5.3) 13.6 2.5 (0.8–8.1)
3 0 — — 8.6 8.4* (4.4 –16.2) 6.7 6.5* (1.4 –30.8)
o4 0 — — 5.4 14.8* (5.7–38.2) 0 — —
MDD, Major depressive disorder ; RBD, recurrent brief depressive disorder; CD, combined depression; OR, odds ratio; CI, confidence
interval.
* P<0.05.
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2000) our data reveal a balanced sex ratio in
RBD, which is significantly different from all
other affective disorders exhibiting an excess of
female gender, which might indicate differences
in underlying sex related risk factors for this
disorders. Other features of RBD, like total
number of episodes and an average duration of
brief depressive episodes have also been in ac-
cordance with previous published studies (Maier
et al. 1994a ; Weiller et al. 1994a, b ; Altamura
et al. 1995; Angst, 2000a). Symptom profiles or
RBD have been similar to sMDD and MDD
although being less pronounced in comparison
to the latter. Only sleep disturbances seem to
have a tendency to be evenmore frequent inRBD
than in MDD. Clinical correlates indicated a
significant impact of RBD on mental health.
Help-seeking behaviour reached a degree of
severity similar to MDD. Suicidal ideation and
suicide attempter status, the most severe psy-
chiatric outcome measure, have been only
slightly less prevalent in RBD than in MDD in
our study, which is supported by other epidemi-
ological studies (Maier et al. 1994a ; Weiller et al.
1994a, b ; Altamura et al. 1995; Angst, 2000a).
Together with clinical studies, which demon-
strated that increased impulsiveness is respon-
sible for the occurrence of suicidal behaviour in
RBD (Montgomery et al. 1989; Pezawas et al.
2002a), our results underline the need for treat-
ment in this underdiagnosed patient group.
RBD showed a more distinct pattern of co-
morbidity than MDD. Furthermore, RBD
seems to be a less multi-morbid condition in
comparison to MDD. Anxiety disorders in-
cluding PTSD were the most frequently found
12-month co-morbidities of RBD. Whereas an
increased co-morbidity of anxiety disorders has
been reported previously (Angst, 1994b), PTSD
has been investigated in the context of RBD for
the first time in this study and turned out as the
highest associated co-morbid condition. It seems
to be noteworthy that RBD lacked a lifetime
association with premenstrual dysphoric dis-
order, which demonstrates that these disorders
are not associated features. Apart from anxiety
disorders alcohol abuse seemed to be the second
major lifetime co-morbid condition of RBD. No
association with hypomania or bipolar disorders
have been found in our sample arguing against
the hypothesis that RBD could be a part of the
bipolar spectrum.
One major aim of the study was to investigate
the hypothesis, that RBD is only an associated
feature of another mental disorder and therefore
might be a type of severity marker. The low
number of co-morbidities and the rather low
associations with co-morbid conditions found
in our study reject that hypothesis. Our data,
including results of prevalence, gender distri-
bution, co-morbidity analysis and clinical cor-
relates support the definition of RBD as a
distinct disorder.
Interestingly, all co-morbid conditions as-
sociated with RBD (anxiety disorders, PTSD,
alcohol abuse) and many features of RBD (de-
pression, suicidal behaviour, impulsiveness) are
thought to be associated with a malfunction of
the serotonergic system (Mann et al. 2001).
However, the first and only published controlled
clinical trial (Montgomery et al. 1994) on the
efficacy of a serotonergic agent inRBD including
patients with repeated suicide attempts revealed
a negative result. Recently, several case reports
(Amore et al. 1998), one open trial (Stamenkovic
et al. 2001) and progress in study design of RBD
therapeutic trials (Pezawas et al. 2002a ; Post
et al. 1998) question this previously found nega-
tive result with serotonergic agents. However,
our findings emphasize the hypothesis (Post &
Weiss, 1998), that the serotonergic system might
be involved in the phenomenon of RBD.
Other than threshold RBD, sRBD seems to
play a minor role. Our data do not support a
major clinical need for a broader definition of
RBD.
Combined depression
Combined depression as defined in our studywas
almost as prevalent as RBD, but shared many
features with MDD like a tendency towards fe-
male gender excess, and exhibited a depression
symptom profile, which was even higher then in
MDD for half of all assessed diagnostic symp-
tom criteria for depression. Clinical correlates
have been similar toMDDexcept suicide attempt
rates. No suicide attempt has been observed in
our CD group. This result is in contradiction
to previous results indicating that CD is a high
risk population for suicide attempts, which has
been found by epidemiological (Angst, 1994b ;
Maier et al. 1994a) and clinical (Montgomery
et al. 1989; Pezawas et al. 2002a) studies. Be-
cause of the low prevalence of subjects with both,
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threshold RBD and MDD, and resulting pro-
blems with statistical power, we decided to in-
clude subthreshold manifestations of RBD and
MDD in the definition of CD. This and the small
number of observed CD cases might be at-
tributable that our subjects did not report suicide
attempts. Nevertheless, suicidal ideation has
been similar to MDD indicating a clinical severe
condition. CD like MDD has been found to
be associated with a bundle of multi-morbidity.
Interestingly, clinically more severe psychiatric
disorders like drug dependence showed ex-
tremely high associations with this condition.
However, apart from the suicide attempter status
our data confirm results of previous studies
(Angst & Merikangas, 1997) indicating that CD
is a more severe condition than MDD.
This study has some limitations. First, RBD
has not been assessed at baseline, which means
that our findings can be seen as lower bound
estimations. On the other hand this situation
provided the possibility to investigate the con-
cept of RBD in a restrictive condition free of any
BIAS towards an overestimation of RBD cases.
Secondly, the definition of CD included sub-
threshold cases for statistical reasons, which
means that our CD group is less severely ill than
it would be for the threshold definition. How-
ever, even using this weak definition of CD, we
could confirm that CD is a more severely dis-
ordered condition than MDD. Nevertheless,
further studies should define CD as threshold
diagnosis in order to assess the severity of this
concept properly.
Our data suggest that RBD is a prevalent
clinical condition among depressive disorders
being at least as prevalent as dysthymia. Fur-
thermore, RBD is associated with significant
clinical impairment sharing many features
together with MDD. However, other features
like gender distribution or co-morbidity patterns
differ essentially from MDD. Furthermore, the
lifetime co-occurrence of both, MDD and RBD
indicates a severe psychiatric condition.
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T. B. Üstün and N. Sartorius), pp. 5–27. Wiley : New York.
Verkes, R. J., Van der Mast, R. C., Hengeveld, M. W., Tuyl, J. P.,
Zwinderman, A. H. &VanKempen, G. M. J. (1998). Reduction by
paroxetine of suicidal behavior in patients with repeated suicide
attempts but not major depression. American Journal of Psychiatry
155, 543–547.
Weiller, E., Boyer, P., Lepine, J. P. & Lecrubier, Y. (1994a). Preva-
lence of recurrent brief depression in primary care. European
Archives of Psychiatry and Clinical Neuroscience 244, 174–181.
Weiller, E., Lecrubier, Y., Maier, W. & Üstün, T. B. (1994b). The
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